Inventor · disambiguated record
Sudhir R. Sahasrabudhe
Also filed as: SAHASRABUDHE SUDHIR R
4 granted patents·7 pending applications·38 citations·filing 1996–2016
73Inventor score
Top patents by PatentIndex Score
11 records- 0191US7615554B2Erastin and erastin binding proteins, and uses thereofPROLEXYS PHARMACEUTICALS INC·Filed 2006·Granted Nov 10, 2009·30 cites·23 claims
- 0274US8518959B2Quinoxaline derivatives as antitumor agentsBECKLIN ROBERT R·Filed 2006·Granted Aug 27, 2013·5 cites·17 claims
- 0369US2011123486A1Methods of treating multiple myeloma and resistant cancersPROLEXYS PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 0468US8575143B23-aryl-substituted quinazolones, and uses thereofQI LONGWU·Filed 2006·Granted Nov 5, 2013·2 cites·28 claims
- 0564US2014227221A1Methods of treating multiple myeloma and resistant cancersPROLEXYS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 0658US2016271133A1Methods of Treating Multiple Myeloma and Resistant CancersPROLEXYS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0753US2016015710A1Methods of Treating Multiple Myeloma and Resistant CancersPROLEXYS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 0852US2009136561A1Non-peptidyl agents with pHSP20-like activity, and uses thereofPROLEXYS PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 0944US2009170834A1Fused Pyrimidones and Thiopyrimidones, and Uses ThereofPROLEXYS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 1043US2005187268A1Non-peptidyl agents with pHSP20-like activity, and uses thereofPROLEXYS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1123US5919631AMethod of determining the degree of aggregation of the β-A4 peptideHOECHST MARION ROUSSEL INC·Filed 1996·Granted Jul 6, 1999·1 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Sudhir R. Sahasrabudhe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →